JAKi Safety and Efficacy in bDMARD-IR Patients with RA: Results Through 5 Years Now in the RheumNow poster hall: Long-term extension outcomes from SELECT-BEYOND through 5 years in bDMARD-IR patients with RA. Sponsored by AbbVie US Medical Affairs. https://t.co/07PrYidnt9 https://t.co/qWM9N68hZ1